IMID clinical trials require a specialized team.

Accelerate your IMID clinical development program with a global leader.

At Worldwide, we understand that each immune-mediated inflammatory disease (IMID) study presents unique challenges among these multifactorial diseases. Our dedicated teams are committed to providing tailored solutions that align with your specific needs, ensuring the success of your clinical program. From initial trial design to market entry, our experts are with you every step of the way.

Get started with Worldwide

Please let us know how we can help by filling out the form

Want a CRO partner who gives you their full attention?

You’re in the right place.

Watch Video
0 +

Therapeutic Experts

0 +

Countries, All Regions

Therapeutic-Informed Approach

Our teams have expertise supporting rheumatoid arthritis, lupus, inflammatory bowel disease, connective tissue disorders, atopic dermatitis, psoriasis, osteoporosis, rare inflammatory disease, asthma, and COPD. We also offer support for small molecules, biologics like biosimilars, and advanced therapies, such as cell and gene therapies.

Award-Winning Project Teams

Our teams are recognized for their excellence and commitment to delivering quality outcomes. They are dedicated to upholding a legacy of success and being accessible to the sponsors they support.

Expertise in Managing Complex Programs

We specialize in supporting complex and innovative trials, providing resources and relationships necessary for success. Our expertise includes handling intricate protocol developments and ensuring seamless trial execution.

0 +

Therapeutic Experts

0 +

Countries, All Regions

0

Locations

Comprehensive Clinical Development Services Across All Phases

Worldwide offers exceptional end-to-end solutions for IMID drug development programs, including:

Icon list

Global IMID Clinical Trials

  • Extensive global footprint in optimal and emerging markets
  • Established pathways for efficient delivery with central labs and imaging
  • Readiness for regulatory inspections
Icon list

Phase I Expertise

  • Precision in Phase I trial designs
  • Efficient cohort management and optimization
  • Comprehensive sample and logistics management
  • Specialized bioanalytical lab services
Icon list

Adaptive & Complex Trial Designs

  • Expertise in adaptive and complex Phase I-II trials
  • Agile data review processes for rapid decision-making
  • Global expansion capabilities with a focus on timely execution
Icon list

Regulatory Support

  • In-depth global and local regulatory expertise
  • Strategic engagements with regulatory agencies
  • Comprehensive strategies for regulatory navigation
Icon list

Patient-Centric Approaches

  • Innovative enrollment strategies to minimize patient burden
  • Dedicated patient navigators and partnerships with advocacy organizations
  • Focused strategy on diversity and inclusion
Icon list

Expertise in Cellular & Genetic Therapies

  • Modality-specific support for diverse treatment approaches
  • Experience in both adult and pediatric phases
  • Specialization in various routes of administration
Icon list

Biomarker and Personalized Medicine

  • Strong alliances with reference and specialty labs
  • Expertise in executing preclinical and screening protocols

Meet Our IMID Experts

Our team delivers tailored and pragmatic advice regardless of the size or complexity of the project. Our collaborative, customized project teams with phase- and indication-specific expertise develop successful strategies for even the most novel therapies.

Meet our team and learn how our approach can transform your IMID trial.

Client Testimonials

Hear from our past customers about their experience with Worldwide:

“Worldwide is an important partner for us. We have a long history with positive experiences… so the relationship is on a fantastic foundation. We also believe in the value of long-term strategic partnerships and certainly see Worldwide as one of our few strategic partners in the future.”

Vice President of Clinical Operations Late Phase: Small Biotech Customer

“The top reasons why we selected Worldwide is that they showed they had the experience and how the team interacted together, all of that collaboration spirit. They weren’t the biggest, and they weren’t the smallest, so it was balancing having the ability to do our trials without us being just a number vs. big CROs that have bigger clients.”

Vice President of Clinical Operations Late Phase: Small Biotech Customer

“Worldwide is an important strategic partner for our company. Worldwide has performed well on our recent clinical studies, and I see no issues that would prohibit us from awarding more clinical studies to them in the future.“  

Sr. Director of Clinical Operations Late Phase: Midsize Biotech Customer

Awards

On May 1st, Industry Standard Research (ISR) announced the 2024 Leadership Awards, recognizing Phase 2/3 CROs for comprehensive excellence across their capabilities, compatibility, expertise, quality, and reliability.

In 2023, Worldwide Clinical Trials was named Most Innovative Clinical Research Organization (CRO) by the Triangle Business Journal (TBJ). This awards program celebrates the achievements of individuals and companies making critical advancements in pharmaceuticals, biotech, ag tech, and beyond, in the Triangle region of North Carolina.

Worldwide Clinical Trials, Inc., (Worldwide) the industry’s leading global, midsize, full-service contract research organization (CRO), has been recognized for excellence and honored in five categories in the 2022 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines. This marks the ninth consecutive year that Worldwide has been recognized as a high-performing CRO based on direct survey feedback from pharmaceutical and biotech professionals.

Over 80% of respondents agreed that midsize CROs, such as Worldwide, provide a strong cultural fit while being able to pivot quickly based on changing customer needs.

Read the full report here